Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Lifts full-year outlook as obesity drug boom accelerates
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
But acquisition charges drag earnings into loss
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
The agreement could rise to $900 million if key commercial milestones are met
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
Subscribe To Our Newsletter & Stay Updated
